Background On the basis of mixed results from previous trials, we assessed whether therapeutic hypothermia for 48-72 h with slow rewarming improved mortality in children after brain injury.
Introduction
Despite preventive measures, severe traumatic brain injury remains a leading cause of paediatric deaths and permanent disability around the world. [1] [2] [3] Therapeutic regimens for paediatric traumatic brain injury, which are often derived from adult studies, have not been shown to be successful in improving outcome in children.
Therapeutic hypothermia has been shown to prevent or reduce secondary injury in animal experiments through several mechanisms including decreased cerebral metabolic demands, infl ammation, lipid peroxidation, excitotoxicity, and cell death, with improved outcomes after experimental traumatic brain injury in mature and immature animals. [4] [5] [6] [7] [8] Therapeutic hypothermia for 24-48 h was also successful in phase 2 and 3 clinical studies 9 of adults after traumatic brain injury and in several clinical trials in newborn babies after hypoxic-ischaemic encephalopathy, 10 with improved outcomes, 11 particularly mortality. Thus, the paediatric guidelines 12, 13 concluded that further study was needed to establish the eff ect of temperature regulation and hypothermia in children after severe traumatic brain injury.
Although a multicentre, phase 3, randomised controlled trial of moderate hypothermia in adults was stopped early owing to futility, 14 post-hoc analysis drew attention to the potential for eff ectiveness in younger patients (aged <18 years). A phase 3, multicentre, international (Canada and Europe) randomised controlled trial of hypothermia (at 32·0-33·0°C) for 24 h initiated within 8 h of severe traumatic brain injury in children and adolescents reported that hypothermia worsened outcomes at 6 months post-injury and possibly increased mortality (21% vs 14%; p=0·06). 15 However, issues related to study design raised concerns about the study fi ndings. 4 Questions remained as to whether altering diff erent parameters-ie, early or extended cooling period-would improve outcome. 15, 16 In view of the results of our phase 2 trial showing reduced mortality using hypothermia in children after severe traumatic brain injury, 16 we aimed to assess whether hypothermia improved outcome-particularly mortality-after injury. Also, on the basis of fi ndings from our preliminary work 16 and issues from the previous randomised controlled trial, 5 our study was designed to ensure early randomisation and initiation of cooling, longer cooling periods, slower rewarming, and strict protocols for management of patients compared with previous paediatric severe traumatic brain injury hypothermia trials.
Methods

Study sites and participants
The Paediatric Traumatic Brain Injury Consortium: Hypothermia (the Cool Kids Trial) was a multinational, multicentre, phase 3 randomised controlled trial assessing the eff ect on mortality of moderate hypothermia with slow rewarming after paediatric severe traumatic brain injury. Hypothermia was maintained for 48-72 h in conjunction with standardised head injury management and compared with normothermia. Patients were enrolled in the emergency department or intensive care unit at study hospitals within 6 h of injury from 15 sites in the USA, New Zealand, and Australia. Parents or guardians of all participants provided written informed consent before enrolment. In some hospitals, children were enrolled via an emergency waiver of consent.
Patients were eligible for inclusion if they were aged 0-17 years; had non-penetrating brain injury, a Glasgow coma scale score of 3-8, and a motor score on the Glasgow coma scale of less than 6 after resuscitation; and were available for randomisation within 6 h of injury (which required known injury time, to exclude children with nonaccidental trauma). Patients were excluded if they had a normal CT, a Glasgow coma scale score of 3, unreactive pupils, hypotension (defi ned as systolic blood pressure <5th percentile for age) for more than 10 min, uncorrectable coagulopathy (prothrombin time/partial thromboplastin time >16/40 s, international normalised ratio >1·7), hypoxia (defi ned as oxygen saturation <90% for >30 min after resuscitation), abbreviated injury severity score of 4 or greater for organs other than the brain, suspected pregnancy, or unavailable parent or guardian to consent (at some study sites-those without emergency waiver of consent). The trial protocol was approved by the Institutional Review and Ethics Boards at each participating centre and allowed emergency waiver of consent (at fi ve of the 15 study sites) if a family member was unavailable.
Randomisation and masking
Patients were randomly assigned in a one-to-one ratio, stratifi ed by site and age (<6 years, 6-15 years, 16-17 years), to hypothermia or normothermia using a web-based random assignment algorithm. Ran domisation was done by the site study coordinator after screening for eligibility. Investigators who assessed outcome were masked to treatment allocation. Emergency service personnel, study nurses involved in randomisation, and personnel who managed the patients were unmasked to treatment Patients were started on tier-one treatment. If treatment failed, the patient was started on tier-two treatment.
Tier one
• Head in a neutral position at 0-30° elevation.
• Intermittent or continuous ventricular drainage of CSF.
• Systemic neuromuscular paralysis (pancuronium or vecuronium) with sedation (confi rmed by non-movement on a twitch monitor) or sedation alone with a continuous infusion of narcotic (fentanyl or morphine).
• Sedation followed by hyperosmolar therapy with either mannitol (initially at 0·25 g/kg every 4-6 h, with escalation to 0·5-1 g/kg until serum osmolality was greater than 320 mOsm per kg) or hypertonic saline (3%) continuous drip (started at 0·1-0·5 mL/kg, up to 1·0 mL/kg, titrated to eff ect to maintain serum osmolality less than 360 mOsm per kg) as needed for intracranial pressure increases.
Tier two
• Treating clinician's choice of the following:
• Option one: barbiturates, initially 5 mg/kg every 4-6 h, with escalation to coma with 80-90% burst suppression by continuous electroencephalogram monitoring 10 s epochs (pressors and further volume expansion were used to maintain central venous pressure, cerebral perfusion pressure, and mean arterial pressure, and to avoid hypotension with higher doses of barbiturates or narcotics). • Option two: decompressive craniectomy, contusion excision, or both, or temporal lobectomy for failure of medical management.
• Phenytoin was given to all patients at 20 mg/kg followed by maintenance doses (of 5 mg per kg per day in three divided doses) for 7 days.
• Blood gases were not corrected for body temperature.
• Central venous pressures and volume and serum potassium concentrations were monitored and treated with intravenous replacement, except for before and during rewarming. PaCO 2 less than 30 mm Hg was avoided through controlled ventilation when possible.
allocation. Anyone involved in obtaining outcomes and outcome data including, psychologists, neuropsychologists, and or neuropsychology technicians, were masked to treatment. A run-in period was used to ensure patient safety and data quality. Requirements for the study to pass beyond the run-in period included entry of one patient assigned to hypothermia and managed according to protocol, and transfer of all necessary data to the data centre. Data from patients in the run-in phase were not included in the analysis.
Procedures
All emergency treatment procedures and specifi c guidelines for head injury management were based on paediatric guidelines 12 and other standardised operating protocols agreed to by consensus of all the site investigators. We used a standard servo-controlled cooling and heating blanket unit placed underneath the patient for temperature regulation and to cool or rewarm patients to the target temperature. Children's temperatures were taken with rectal or brain temperature probes.
Patients in the hypothermia group were rapidly cooled initially using iced saline (4°C) to 34-35°C and then surface cooled to 32-33°C and maintained for the requisite 48 h period. The patient was then rewarmed by 0·5-1·0°C every 12-24 h as part of a slow rewarming protocol. If at 48 h their intracranial pressure (ICP) was high (>20 mm Hg) a further 24 h of cooling at target (32-33°C) was maintained. At this point, rewarming occurred, irrespective of ICP levels, albeit slowly (<1·0°C every 24 h) to prevent rebound intracranial hypertension. Patients in the normothermia group were maintained at 36·5-37·5°C. Patients with temperatures greater than 38°C were treated with rectal acetaminophen and cooling blankets.
The main goals of therapy in intensive care units and operating rooms were to avoid hypotension, hypoxia, and intracranial hypertension by: maintaining mean arterial pressure (MAP) at within two SD of the mean for their age, 12, 13 peripheral oxygen saturation greater than 90%, and ICP less than 18 mm Hg (for children aged <6 years), ICP of 20 mm Hg or lower (≥6 years), and or cerebral perfusion pressure greater than MAP (for their age) plus 20 mm Hg. A two-tiered protocol was followed in a stepwise linear manner with failure of the fi rst-tier treatment dictating escalation to second tier treatments (panel 1). All physiological data, daily fl uid volumes, drugs and dosages, neurological and Glasgow coma score, and daily paediatric intensity level of therapy scores were recorded over the fi rst 7 days of admission to hospital. 167 Our primary outcome, assessed by intention-to-treat analysis, was mortality at 3 months after injury.
We hypothesised that induced early cooling (<6 h) with hypothermia (32-33°C) after paediatric severe traumatic brain injury maintained for 48 h would reduce all-cause mortality at 3 months after injury compared with normothermia (36·5-37·5°C). The secondary outcome measures were global function at 3 months after injury using the Glasgow outcome scale (GOS) and Glasgow outcome scale-extended pediatrics (GOS-E Peds) as well as the occurrence of serious adverse events and adverse events. GOS scores were dichotomised into good outcomes for good or moderate functional disability (GOS 1 and 2, respectively) or poor outcomes for those who were severely disabled, were vegetative, or died (GOS 3, 4, or 5, respectively). GOS-E Peds scores were also dichotomised into good outcomes (GOS-E Peds 1-3) and poor outcomes (GOS-E Peds 4-8).
Statistical analysis
On the basis of fi ndings from our previous trial, 16 the planned sample size was 340 patients, which would allow detection of a 10% diff erence in the percentage of patients who died with 80% power. An interim analysis of outcome and complications was planned at the midpoint of the trial (when 170 people had been enrolled analyses were done every 6 months in conjunction with the data safety and monitoring board meeting. A group sequential analytic approach was used to adjust the overall type-1 error for multiple comparisons. Stopping rules stated that the trial should be terminated at the futility or interim analysis if there was less than a 20% chance of confi rming the primary hypothesis. Baseline characteristics by treatment group are reported as means and SDs for continuous variables and percentages for discrete variables. We compared functional outcomes and the occurrence of serious adverse events using a Pearson χ² test or a Fisher's exact test. We used a logistic regression model to assess the probability of mortality up to 3 months after injury; we selected this model because we wanted to assess the association of treatment with mortality by a specifi c timepoint, not to estimate the risk of mortality at any given time. We used SAS (version 9.2) for statistical analyses, which included only patients randomly allocated to the one of the two treatment groups only (ie, no run-in patients).
This trial is registered with ClinicalTrials.gov, number NCT00222742.
All (N=77)
Hypothermia ( Role of the funding source
The sponsor had no role in data collection, analysis, or interpretation, or in writing the report, but was involved in study design and chose the timing of the futility analysis. The corresponding author had full access to all the data at the completion of the study and had fi nal responsibility for the decision to submit for publication.
Results
Because of slow accrual and concerns from the data safety and monitoring board about safety data from another randomised controlled trial 15 in children with severe traumatic brain injury treated with hypothermia for 24 h (p=0·14), a futility analysis was done and the trial was stopped in Feb 28, 2011.
We had randomly allocated 77 patients to treatment: 39 to hypothermia and 38 to normothermia (written consent was given for 74 patients, the other three had an emergency waiver of consent; fi gure 1).
Three hypothermia-treated patients were later found to meet exclusion criteria: one child had an unknown time of injury related to assault, one child had a complete spinal cord injury and physiological decapitation (both children later died), and one child improved after resuscitation to a Glasgow coma scale score greater than 8. No patients in the normothermia group later met exclusion criteria. Three sites enrolled 75% of the randomised patients: Children's Hospital of Pittsburgh, PA, USA (23 patients), University of California, Davis, CA, USA (12 patients), and University of Texas, Southwestern, TX, USA (ten patients). Follow-up for primary and secondary outcome measures continued until May 28, 2011.
Baseline characteristics were much the same between the two groups apart from the median size of the right pupil, which was larger in the hypothermia group than it was in the normothermia group (tables 1 and 2).
The primary outcome of mortality within 3 months of injury, available for all 77 patients, did not diff er between hypothermia-treated patients (6 [15%] of 39 patients) and normothermia-treated patients (2 [5%] of 38 patients; p=0·15) when the trial was stopped. Secondary outcome data were missing for two patients: one (in the hypothermia group) was lost to follow-up at 3 months for global function, and one (in the normothermia group) had missing data for GOS-E Peds. We detected no signifi cant diff erence between the interventions in categorical GOS and GOS-E Peds scores (fi gure 2) or in the dichotomised (good or poor) GOS and GOS-E Peds scores at 3 months (table 3) . 37 (95%) of 39 patients assigned to hypothermia were cooled for at least 48 h before rewarming; one progressed rapidly to brain death before cooling and the other improved substantially and was rewarmed before completing 48 h of cooling. Of the remaining 37 cooled patients, mean time to randomisation and initiation of cooling was 5 h 8 min (SD 55 min) after injury, although three patients who were allocated to the hypothermia group before 6 h after injury began cooling at more than 6 h after injury. All patients in the hypothermia group reached target temperature (32-33°C) with mean time to target from injury of 9 h 0 min (3 h 10 min; range 4 h 31 min to 22 h 18 min). Seven (18%) of 38 patients reached target within 2 h of initiation of cooling (range 0 h 0 min to 1 h 58 min).
Mean temperature for the 48 h period of hypothermia was 32·9°C (SD 0·8) and for the concurrent 48 h period in the normothermia group was 36·9°C (SD 0·7; p<0·0001 for between-group diff erence). No patient assigned to normothermia was cooled lower than 36·5°C. Normothermic temperature (36·5-37·5°C) was maintained for 48 h in 12 (32%) of 38 patients in the normothermia group. Rewarming for hypothermia patients occurred with a mean temperature of 32·8°C (SD 0·5) with mean time of rewarming to 36°C of 60 h 5 min (SD 26 h 26 min; fi gure 3).
We recorded no diff erences in medical management, mean arterial pressure, or cumulative fl uid balances between the treatment groups, but a higher proportion of Data are number of patients (%). *Between-group diff erence (p value=0·90). †Between-group diff erence (p value=0·73). Despite random assignment, there were missing data for two patients: one patient was lost to follow-up at 3 months, and Glasgow outcome scale-extended pediatrics data were missing for one patient in the normothermia group. 
Discussion
This trial was stopped due to futility because hypothermia, initiated early, used globally for 48-72 h, and with a slow rewarming period, did not improve mortality or global function 3 months after injury compared with normothermia. Although many therapeutic interventions for severe traumatic brain injury have been used and tested in clinical trials, no new treatment regimens-for adults or children-have been shown to be eff ective. 5, 18, 19 Hypothermia has alleviated secondary brain injury after acute brain injury in both adult and immature animal models of injury, including traumatic brain injury. 7, 8, [20] [21] [22] [23] [24] This trial expanded on the few previous, limited, and small-scale, hypothermia clinical studies in paediatric severe traumatic brain injury and on the only three randomised controlled trials (panel 2). Findings from an international phase 3 multicentre randomised controlled trial of hypothermia 15 in 225 children with severe traumatic brain injury indicated that delayed initiation of cooling, cooling for up to 24 h, rapid rewarming, and hypotension in the acute period after injury should be avoided. Thus, in the present study, we attempted to build on the available evidence by starting cooling earlier, for a longer duration (48 h), and with slow rewarming while maintaining perfusion by avoiding hypotension with fl uids and pressors. We saw no diff erence in mortality or 3 month global function, as was the case in the other randomised controlled trials of hypothermia in adults 9, 14 and in children, 15 but by contrast with our previous phase 2 trial in which hypothermia improved mortality. 16 There are several limitations and potentially confounding variables (ie, age-related changes in brain development, similar aged children at diff erent levels of maturity) in clinical trials for traumatic brain injury, especially in trials done with children. Other design approaches can be considered that would increase the necessary sample size. Although the Glasgow coma score has been the mainstay for initial assessment of severity of brain injury and then inclusion in clinical trials, the types and variability of pathology seen on imaging despite similar Glasgow coma score emphasise the need for improved initial assessment for stratifi cation into clinical studies. For example, hypothermia might have selective effi cacy in particular types of pathology-eg, surgically evacuated haematomas versus diff use injury-which could be used as the selection criteria rather than Glasgow coma score. 29 Despite consensus of site investigators to a step-wise clinical pathway for management of intracranial pressure, application of that algorithm varied both within and between sites, with variations in treatment potentially confounding results and contributing to futility. In Data are n (%), mean (SD), or n/N (%). Table 4 : Adverse events particular, decompressive craniectomy was used for intracranial pressure control in more patients in the normothermia group than in the hypothermia group. Further prospective studies of a large number of patients, across multiple centres, are needed to assess the comparative eff ectiveness of this variability in the management of these children and their intracranial hypertension.
Similarly, outcome assessment after injury is not easily defi ned. On the basis of our previous fi ndings, 16 we used mortality as our primary outcome measure for the present study because its measurement gave the largest diff erence in our paediatric patients, and we used it to calculate the sample size. During the accrual period for this study, mortality of children after brain injury in the USA decreased overall, lessening the power of the study. Furthermore, during the accrual period, the incidence of non-accidental trauma as the mechanism of injury seemed to increase. Because this type of injury was an exclusion criteria (because of diffi culty in determining the exact time of injury), many children with severe nonaccidental injuries were excluded, further reducing power.
In children, traumatic brain injury aff ects not only a wide range of functional abilities, but also normal development, 30 and global outcome measures (GOS and GOS-E Peds) that depend heavily on parent or caregiver report of signs and symptoms might have little usefulness in the assessment of functional outcome after paediatric brain injury.
Finally, consent could not be obtained for many potentially eligible patients for the following reasons: distance to paediatric study centres (parents or guardians were often not available for consent within the requisite time for randomisation and initiation of cooling); inability to obtain emergency waiver of consent at most of the sites (present day regulations and compliance for emergency waiver requirements-eg, community education-cannot be budgeted into the cost of the study and are often prohibitively expensive in large studies); and a higher rate of refusal of consent from parents and guardians than in the previous study. The reasons for the higher rate of refusals are unclear, but this fi nding does cause concern for future studies of acute therapeutic intervention if accessibility to paediatric patients becomes diffi cult.
Further clinical trials will need improved stratifi cation by injury and alternative outcome measures if they are to be able to establish the potential of hypothermia to treat children with severe traumatic brain injury.
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Confl icts of interest
Interpretation
We identifi ed only three randomised controlled clinical trials 15, 16, 25 that tested therapeutic hypothermia after severe traumatic brain injury in children. Biswas and colleagues' trial 25 was a small study underpowered for outcome and its fi ndings were inconclusive with respect to mortality, although it did show that hypothermia lowered intracranial pressure. We previously reported a phase 2 randomised controlled trial in which moderate hypothermia (32-33°C) for 48 h did improve outcome (Glasgow outcome scale) with decreased mortality. 17 Since our previous study, phase 3 randomised trials were done by Clifton and colleagues 9, 14 in adults (moderate hypothermia, early cooling, for 48 h, and then slow rewarming) and Hutchison and colleagues 15 in children (moderate hypothermia for 24 h, then rapid rewarming), all reporting no improvement in mortality or global functional outcome after severe traumatic brain injury. The present study was stopped early owing to futility, showing that moderate hypothermia (32-33°C) for 48-72 h with slow rewarming after severe paediatric traumatic brain injury did not improve outcome with regard to mortality or global function at 3 months after injury. These few studies have not shown benefi cial eff ects of therapeutic hypothermia in the clinical setting after paediatric brain injury. Further research might be benefi cial to assess whether there is the potential effi cacy of therapeutic hypothermia in severe traumatic brain injury in children under other circumstances. Such studies could include investigation of cooling temperature, timing, and injury type, as well as long term follow-up with alternative measures.
